ISB 2001 demonstrated a favorable safety and tolerability profile, and an overall response rate (ORR) of 75% in r/r MM
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program
CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus
Revolf's infertility and miscarriage tests are a new technology that uses blood tests to detect neoself-antibodies
Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI
Spread over 1.26 lakh sq ft building, the super-specialty eye hospital will perform 30,000 free eye surgeries annually for economically weaker sections
Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
Results from the open-label extension study of PHOTON demonstrate patients with diabetic macular edema (DME) randomized to Eylea 8 mg maintained visual and anatomic improvements at the end of three years
Subscribe To Our Newsletter & Stay Updated
